Net Medical Xpress Solutions (OTCMKTS:NMXS) Stock Surges Following Q4 Results

Net Medical Xpress Solutions (OTCMKTS: NMXS) was up 11%, and the stock is up 21% in a week. The company had announced that it had a net income of $301,285 and total revenue of $821,399 for the fourth quarter ending December 31, 2021.

Trading Data

On Tuesday, NMXS stock surged 11.27% to $0.0790 with more than 17.8K shares, compared to its average volume of 14.6K shares. The stock moved within a range of $0.0640 – 0.0790 after opening trade at $0.0748.  

Earnings Recap

The company‘s CEO Dick Govatski said that COVID tests, which were performed through the company’s state-of-the-art portable testing facilities, were in high demand. In addition, the usage of bioMerieux’s patented PCR diagnostic module, which gives speedy certified findings that may be utilized for traveling and other reasons, benefited Net Medical Xpress patients.

Currently, the test is the only FDA-approved assay that can discover and confirm 22 different viral infections, including Covid, Influenza, and the common cold.In addition, the firm’s mobile fleet of vehicles provides statewideCOVID and FLU screening for schools, businesses, nursing homes, and homeless shelters. The lab also acts as a reference laboratory for doctors’ offices and other institutions that lack complicated virus testing capabilities. So investors should watch NMXS.

Key Quote

Net Medical CEO Dick Govatski said, “Demand was high for Covid tests provided through our state-of-the-art mobile testing labs. Our patients benefited from our use of bioMerieux’s proprietary PCR testing module that provides quick certified results that can be used for travel and other purposes. It is the only FDA approved test that can detect and identify 22 separate viral pathogens including Covid, influenza and the common cold.”

Technical Data

NMXS stock is trading above the 20-Day and 50-Day Moving averages of $0.0674 and $0.0656 respectively. Moreover, the stock is trading above the 200-Day moving average of $0.0577.